Journal Pre-proof

Infections in children and adolescents with hematological malignancies

Andishe Attarbaschi, Thomas Lehrnbecher



PII: S2772-610X(23)00130-7

DOI: https://doi.org/10.1016/j.ejcped.2023.100132

Reference: EJCPED100132

To appear in: EJC Paediatric Oncology

Received date: 22 November 2023 Accepted date: 23 November 2023

Please cite this article as: Andishe Attarbaschi and Thomas Lehrnbecher, Infections in children and adolescents with hematological malignancies, *EJC Paediatric Oncology*, (2023) doi:https://doi.org/10.1016/j.ejcped.2023.100132

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier.

Journal Pre-proof

Infections in children and adolescents with hematological malignancies

Authors:

Andishe Attarbaschi^{1,2,} and Thomas Lehrnbecher³

Corresponding author:

Dr Thomas Lehrnbecher

Email: thomas_lehrnbecher@yahoo.com

Institutions:

¹Pediatric Hematology and Oncology. St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria

² St. Anna Children's Cancer Research Institute, Vienna, Austria

³ Department of Pediatrics, Division of Hematology, Oncology and Hemostaseology, Goethe University Frankfurt, Frankfurt, Germany

Keywords:

hematological, malignancies, children, Infections

With this special issue "Infections in children and adolescents with hematological malignancies", the European Journal of Cancer (EJC) Pediatric Oncology (PO). addresses an important topic of supportive care in pediatric hemato-oncology, if not the most relevant one, as infectious complications are not only associated with high morbidity and decrease the quality of life, but can also be life-threatening and eventually fatal. While for example cure rates in childhood acute lymphoblastic leukemia (ALL) are exceeding 90%, it seems of utmost importance to intensify the efforts in a better understanding, prophylaxis, diagnostics and treatment of infectious complications in order to avoid treatment-related fatalities which, at the moment, still are at 3% in pediatric patients with primary ALL. This rate of treatment-related mortality approaches the current rate of relapsed (6-10%) and refractory disease (0.5%), which underlines the importance of this topic.

Children are not small adults - it has been recognized for a long time that pediatric patients differ from adults in many aspects. For example, the most common pediatric malignancies are acute leukemias, whereas in adults, epithelial cancers of the lungs, colon, prostate and breast are mostly diagnosed [1]. As a result, treatment strategies are different, and treatment intensity and treatment density are higher in the pediatric setting as compared to adults, and result in protracted episodes of neutropenia (and lymphopenia) and mucosal damage as the most important risk factors for infections. However, it is important to note that, compared to adults, children less often suffer from significant comorbidities such as type II diabetes, lung or cardiovascular disease, which therefore allows doseand time-intensified polychemotherapies and allogeneic stem cell transplantations with myeloablative conditioning regimens. Other differences between pediatric and adult patients are related to the different potence of their immune system, including the maturation and regeneration after intensive chemotherapy [2, 3]. Last, a number of therapeutic

compounds, both for chemotherapy and supportive care, are still not approved in the pediatric setting, and for many of them, sufficient data on pharmacokinetics and pharmacodynamics are lacking. These differences between children and adults led to a number of regularly up-dated pediatric-specific guidelines of supportive care in hemato-oncology with a specific emphasis on infectious disease management.

The present special issue of the EJC PO focuses on infectious complications in pediatric hemato-oncological patients, and is therefore important for all pediatric hemato-oncologists and stem cell transplantation experts. This issue will cover the most important aspects of epidemiology, prophylaxis, diagnostics and therapy of infectious complications in the pediatric hemato-oncological setting, but at the same time critically review the implementation of pediatric-specific guidelines. While König et al. will report comprehensively on the state-of-the-art diagnostics and therapy of pediatric patients with febrile neutropenia, Spielberger et al. will show by a point prevalence study a relevant lack of concordance between national / international guidelines and local guidelines across German and Austrian centers for the management of pediatric hemato-oncological patients with febrile neutropenia [4, 5]. Two other articles will address the relevance of viral infections in patients with hematological malignancies: Rauwolf et al. report on prophylactic, pre-emptive and therapeutic strategies of the most important viral infections in the allogeneic stem cell transplantation setting, while Santolaya et al. focus on respiratory viral infections as an important differential diagnosis in patients with febrile neutropenia, enabling both the decrease of broad-spectrum antibiotics and the reduction of in-patient days in the hospital and avoidance of antibiotic resistance [6, 7]. Moreover, Carless et al. will comprehensively review the risk of bacterial and fungal infections in children and adolescents with haematological malignancies [8] and, last but no least, Yap et al. will provide a systematic review on bacterial bone and joint infections of children with

leukemia or undergoing allogeneic stem cell transplantation - a rare but challenging infectious complication with almost no literature available to date [9].

We would like to thank the Editorial Board of the EJC to launch PO, and all the authors of the articles for their valuable contribution to this special issue. We hope that all readers will enjoy reading these five articles which may not only have an educative effect but also arouse their interest in infections in children and adolescents with hematological malignancies.

Funding: None

Conflict of Interest: None

References

- Sung L, Phillips R, Lehrnbecher T: Time for paediatric febrile neutropenia guidelines - children are not little adults. *European Journal of Cancer* 2011, 47(6):811-813.
- Lehrnbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ: Therapyinduced alterations in host defense in children receiving chemotherapy. J Ped Hematol Oncol 1997, 19:399-417.
- 3. Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, Chanock SJ: Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. *The Lancet Oncology* 2008, 9(3):269-278.
- König C and Lehrnbecher T: Diagnostics and therapy of paediatric patients with febrile neutropenia. *European Journal of Cancer PO* 2023, DOI: https://doi.org/10.1016/j.ejcped.2023.100116
- 5. Spielberger BD, Hufnagel M, Reifenrath K, Simon A, Last K, and Papan C: Discrepancies between national and local guidelines for the management of paediatric oncology patients with fever and neutropenia (FN): a need for alignment? European Journal of Cancer PO 2023, DOI: https://doi.org/10.1016/j.ejcped.2023.100030
- 6. Rauwolf K and Pichler H: Virus infections after allogeneic stem cell transplantation in children. *European Journal of Cancer PO* 2023
- 7. Santolaya ME, Delgado-Araneda M, Torres JP. Respiratory Viral Infections in Pediatric Hematology/Oncology Patients. *European Journal of Cancer PO* 2023, DOI: https://doi.org/10.1016/j.ejcped.2023.100119
- 8. Carless F and Lopes de Sousa AV: Infections in children and adolescents with haematological malignancies. *European Journal of Cancer PO* 2023

9. Yap N, Tsoi SK, Boast A, and Haeusler GM: Bacterial bone and joint infections in children with leukemia or following haematopoietic cell transplant: A systematic review of published cases. *European Journal of Cancer PO* 2023, DOI: https://doi.org/10.1016/j.ejcped.2023.100118



Declaration of interests

oximes The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.	
☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:	